Phase 2 Stroke Trial, Recruiting NCT07334977 Sponsor: Centre National de la Recherche Scientifique, France Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT07334977
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Control Group (people without a stroke or spinal cord injury):

  • Adults aged 18 or over
  • People who have signed a consent form agreeing to take part
  • People covered by the French social security system

Post-Stroke Group:

  • Adults aged 18 or over who had a stroke more than 3 weeks ago
  • People whose doctor considers them medically stable
  • People who have signed a consent form agreeing to take part
  • People covered by the French social security system

Spinal Cord Injury Group:

  • Adults aged 18 or over with a complete or incomplete spinal cord injury (rated A through D on a standard injury scale called the ASIA Impairment Scale)
  • People whose doctor considers them medically stable
  • People with paralysis affecting all four limbs due to a neck-level spinal cord injury
  • People who have signed a consent form agreeing to take part
  • People covered by the French social security system

Who may not be able to join:

  • People living with an ongoing long-term health condition
  • People with skin problems or open wounds
  • People with a history of epilepsy or seizures
  • People with certain medical devices or conditions that make MRI or magnetic/electrical brain stimulation unsafe, including a heart pacemaker, an implanted hearing aid, metal fragments in the eye, a history of working with metal, a neurostimulator, or severe claustrophobia (fear of enclosed spaces)
  • People with implanted medical devices — such as heart valves, vascular implants, brain shunts, surgical clips, metal stitches or staples, stents, or bone hardware — that have not been officially cleared as safe for MRI use under an international safety standard
  • People who are legally under the care or protection of a guardian or court-appointed representative
  • Women who are pregnant or breastfeeding
  • People who do not wish to be told if an unexpected finding is discovered during their MRI scan

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Fabien Wagner, PhD, Institute of Neurodegenerative Diseases, CNRS UMR 5293

Phone: +33 5 33 51 48 46

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Centre National de la Recherche Scientifique, France
Registry
ClinicalTrials.gov
Start date
11 December 2024
Est. completion
31 July 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Sensory Performance; Quantitative Prehension Performance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov